Risk factors for pancreatic adenocarcinoma and prospects for screening.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

1. Quantitative Metabolomics and Lipoprotein Analysis of PDAC Patients Suggests Serum Marker Categories for Pancreatic Function, Pancreatectomy, Cancer Metabolism, and Systemic Disturbances.Journal of proteome research · 2024
   Article
2. Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm.Biochimica et biophysica acta. Reviews on cancer · 2023
   Review
3. Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer.Journal of biomedical informatics · 2022
   Article
4. Current State of "Omics" Biomarkers in Pancreatic Cancer.Journal of personalized medicine · 2021
   Review
5. Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.Cellular oncology (Dordrecht, Netherlands) · 2020
   Review
6. Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).Biochimica et biophysica acta. Reviews on cancer · 2020
   Review
7. An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer.Cancers · 2019
   Article
8. LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451.International journal of oncology · 2018
   Article
9. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.Journal of cancer research and clinical oncology · 2015
   Article
10. Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease.Molecular & cellular proteomics : MCP · 2014
    Article
11. Diagnosis of pernicious anemia and the risk of pancreatic cancer.Pancreas · 2014
    Article
12. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.Journal of gastrointestinal oncology · 2012
    Article
13. Molecular biology of pancreatic cancer.World journal of gastroenterology · 2011
    Review
14. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.Indian journal of surgical oncology · 2011
    Article
15. Familial pancreatic cancer.Cancers · 2010
    Article
16. Cyfra 21.1: A Useful Tumour Marker in Pancreatic Ductal Adenocarcinoma: Cross-Sectional Study.Cancer control : journal of the Moffitt Cancer Center
    Article
17. How early can pancreatic cancer be recognized? A case report and review of the literature.Case reports in oncology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

9 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as